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INTRODUCTION {#s1}
============

Seronegative celiac disease (SNCD) is characterized by negative anti-tissue transglutaminase antibodies (anti-tTG) in the presence of histological findings consistent with celiac disease (CD) and associated human leukocyte antigen (HLA) haplotype, DQ2 and/or DQ8.^[@R1]^ Although CD as a cause of duodenal villous atrophy (DVA) is commonly seen, but the presence of DVA with negative serology leads to diagnostic dilemma. Various etiologies associated with DVA and absence of celiac serology include small intestinal bacterial overgrowth, Crohn's disease, intestinal lymphoma, collagenous sprue, and tropical sprue. As a lifelong commitment to gluten free diet (GFD) is required for the treatment of CD, these diseases are needed to be excluded prior to ultimate diagnosis.^[@R2]^

It has been proposed that seronegativity in these patients occurs due to deposition of immune complex deep into intestinal lamina propria, which does not reach the blood vessels. Immaturity of plasma cells is another hypothesis in the mechanism of SNCD. The treatment of SNCD is debatable. Some authors advocate the use of GFD while others refute it.^[@R1]^

No study in Pakistan is available regarding SNCD. The aim of this study was to evaluate the clinical characteristics of SNCD and its response to GFD in patients who presented at a single tertiary care hospital of Karachi, Pakistan.

MATERIALS AND METHODS {#s2}
=====================

This prospective, observational study was conducted at the Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan. Ethical approval was sought from the institutional ethics committee.

SNCD was defined as having all of the following features; marked DVA on duodenal biopsy, negative anti-tTg IgA and IgG, and HLA DQ2 or DQ8 serotype in the presence of compatible clinical features.^[@R1]^ Response to GFD was not used as a diagnostic criterion.

DVA was confirmed and classified according to Marsh classification by histopathological evaluation on duodenal biopsy sample. Patients with giardiasis, small intestinal bacterial overgrowth, human immunodeficiency virus (HIV), collagenous sprue, and tropical sprue were excluded.

All patients fulfilling the criteria of SNCD from January 2009 to December 2015 were included in the study. All the patients' demographics, clinical characteristics, and laboratory parameters were recorded. All the patients were counseled by nutritionist for GFD, and diet charts were also provided. The patients were followed up by the primary researcher and nutritionist to check compliance. Response was assessed clinically by improvement in symptoms and signs and labeled as complete when the patients' presenting symptoms improved or settled completely on GFD (\>70 % improvement) and partial when some of the symptoms improved (eg. diarrhea settled without weight gain). The duration at which the response was achieved was also noted.

The patients' demographics, clinical, and laboratory features and response to GFD were analyzed. Statistical analysis was performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). All continuous variables were represented by median±interquartile range (IQR). Categorical variables were represented by frequencies and percentages. No inferential statistics were applied.

RESULTS {#s3}
=======

A total of 12 patients were included in this study with median age of 31.5 years (IQR: 19.75-46.75 years), out of whom five (41.6%) were men. The clinical and laboratory parameters of individual patients are shown in [table 1](#T1){ref-type="table"}. The presenting complaints were: weight loss in 11 (91.6%), abdominal pain in 9 (75%), diarrhea in 7 (58.3%), and amenorrhea in 2 (16.6%) patients. Median weight at presentation was 39 kg (IQR: 32.50--57.50kg).

###### Main demographic, clinical, and laboratory features of individual patients with seronegative celiac disease

  --------- ----------------- ------------ -------------------------- --------------------------------------- ------------------ -------------------- ---------------------- -------------------- -------------------------
  **No.**   **Age (y)/Sex**   **Weight**   **Associated Diagnosis**   **Presenting features**                 **HLA**\           **Biopsy**\          **Villous atrophy**\   **Response to**\     **VA follow up Biopsy**
                                                                                                              **DQ2/8**          **Marsh**\           **(VA)**               **GFD**              
                                                                                                                                 **classification**                                               

  **1**     40/F              30           Nil                        Diarrhea                                heterozygous DQ8   3b                   Subtotal               Diarrhea improved\   Mild
                                                                                                                                                                             Wt gain              

  **2**     20/F              35           Nil                        Weight loss, abdominal pain             homozygous DQ8     3a                   Partial                Wt gain              Normal

  **3**     23/F              39           NASH CLD                   Weight loss, abdominal pain, diarrhea   homozygous DQ2     3c                   Total                  Diarrhea improved    Not done

  4         19/F              35           ESRD+HTN                   Weight loss, abdominal pain             homozygous DQ2     3a                   Partial                Wt gain              Not done

  5         22/M              39           SMA Syndrome               Diarrhea, weight loss, abdominal pain   heterozygous DQ8   3c                   Total                  Not improved         Total

  6         17/F              30           Nil                        Weight loss, abdominal pain             heterozygous DQ2   3a                   Partial                Wt gain              Not done

  7         40/M              65           Nil                        Diarrhea, weight loss                   heterozygous DQ2   3a                   Partial                Diarrhea improved\   Partial
                                                                                                                                                                             Wt gain              

  8         60/M              50           IBD/Pulmonary TB           Diarrhea, weight loss                   heterozygous DQ2   3a                   Partial                Diarrhea improved\   Not done
                                                                                                                                                                             Wt gain              

  9         45/F              50           EHPVO                      Weight loss, abdominal pain\`           heterozygous DQ2   3b                   Subtotal               Wt gain              Normal

  10        52/M              65           Nil                        Diarrhea, weight loss, abdominal pain   homozygous DQ2     3b                   Subtotal               Diarrhea improved    Not done

  11        32/F              36           Nil                        Weight loss, abdominal pain             Homozygous DQ2     3b                   Subtotal               Wt not improved      Subtotal

  **12**    31/M              40           Nil                        Weight loss, abdominal pain             heterozygous DQ2   3a                   Partial                Wt not improved      Subtotal
  --------- ----------------- ------------ -------------------------- --------------------------------------- ------------------ -------------------- ---------------------- -------------------- -------------------------

CLD, chronic liver disease: EHPVO, extrahepatic portal vein obstruction; ESRD, endstage renal disease; HTN, hypertension; SMA, superior mesenteric artery; IBD, inflammatory bowel disease, NASH, non-alcoholic steatohepatitis; TB, tuberculosis; VA, villous atrophy

On physical examination, pedal edema was observed in five (41.6%) patients. Anemia was found in 10 (83.3%) patients with median hemoglobin of 9.5 g/dL (IQR: 6.3-13.25 g/dL) and median mean corpuscular volume (MCV) was 85 fL (IQR: 65.25--86.65 fL). One patient presented with jaundice and had gastroesophageal varices associated with extrahepatic portal vein obstruction (EHPVO) and portal biliopathy. One patient had associated non-alcoholic fatty liver disease (NAFLD)-related cirrhosis.

On laboratory analysis, median creatinine was 1.6 mg/dL (IQR: 0.64-1.01), median alanine transaminase (ALT) was 21 U/L (IQR: 13--27 U/L), and median albumin was 3 g/dL (IQR: 2.4-3.6 g/dL). HLA DQ serotyping showed homozygous DQ2 and DQ8 in four and one patients, respectively while heterozygous DQ2 and DQ8 in five and two patients, respectively ([figure 1](#F1){ref-type="fig"}). All the patients had negative tests for anti-tTg IgA and IgG. Duodenal biopsies showed marked villous atrophy. Among these, six patients had partial (Marsh class IIIa), four had subtotal (Marsh class IIIb), and two had total villous atrophy (Marsh class IIIc), as shown in [table 1](#T1){ref-type="table"} and illustrated in [figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. Repeat biopsies were performed in seven patients. Among them, three showed improvement in villous architecture, three showed no change in histology, and one showed worsening of villous stunting, as shown in [table 1](#T1){ref-type="table"}.

![HLA DQ distribution in patients with seronegative celiac disease (n=12)](mejdd-9-94-g001){#F1}

![Histology of representative cases. A: Duodenal biopsy showing partial villous atrophy, Marsh class IIIa (H&E, ×200). B: Duodenal biopsy showing subtotal villous atrophy, Marsh class IIIb (H&E, ×200).)](mejdd-9-94-g002){#F2}

![Histology of representative cases. A: Duodenal biopsy showing total villous atrophy, Marsh class IIIc (H&E, ×200). B: High-power view of duodenal biopsy showing markedly increased intraepithelial lymphocytes and Paneth cell hyperplasia (H&E, ×400).](mejdd-9-94-g003){#F3}

All patients were advised to receive GFD; out of them, nine (75%) patients showed complete clinical response. Among the remaining three patients, two were non-compliant, while one patient with NAFLD-related cirrhosis had partial clinical response with improvement in diarrhea. Out of the nine responders, two patients showed response within 6 months while the remaining showed clinical improvement over a year.

DISCUSSION {#s4}
==========

CD is a small bowel disease characterized by villous atrophy, epithelial lymphocytic inflammation, and crypt hyperplasia in genetically susceptible patients in response to dietary gluten. Its diagnosis is dependent on the combination of clinical features, serological positivity, and genetic and histopathological findings.^[@R3]^ Although, duodenal biopsy remains as the "gold standard", but the histopathological findings are non-specific for the diagnosis of CD.^[@R4],[@R5]^ DVA with negative celiac serology is seen in various diseases and SNCD is one of such novel entities. The presence of HLA DQ2 and or DQ8 is required for the diagnosis of SNCD.^[@R1]^ Even with scanty data, the reported prevalence of SNCD ranges from 1.03% to 28%.^[@R6]^ There is no data in Pakistan regarding its prevalence. We are reporting 12 patients with SNCD over a period of 6 years at one tertiary care center in Pakistan. However, it must be clear that the prevalence of this disease cannot be estimated from this small case series from a single center in Pakistan.

The exact pathogenesis of SNCD is not known. It is however hypothesized that in patients with seropositive CD, the tTG and anti-tTG immune complexes are deposited in the mucosa and crossover to enter the blood stream. On the other hand, in SNCD, the antigen-antibody complexes are deposited deep into the lamina propria and are unable to reach the blood stream, thus, explaining the possible reason of seronegativity in such patients. Another proposed mechanism of seronegativity is the immaturity of plasma cells, which fail to produce antibodies.^[@R1]^ Anti-tTG IgA can be negative in the presence of serum IgA deficiency, which occurs in 2- 3% of patients with CD.^[@R3]^ However, most of the patients with such IgA deficiency can produce positive IgG based serological test.^[@R5]^ In our study population, neither any patient was serum IgA deficient nor there was an anti-tTG IgG positivity.

The positivity of anti-tTG has been directly associated with the degree of DVA in various studies. Abrams and colleagues^[@R7]^ described SNCD and reported that although anti-tTG IgA was performed in only 14 patients, negative serology was associated with partial villous atrophy in contrast to total villous atrophy in seropositive patients. We also encountered higher prevalence of partial villous atrophy (six patients). However, subtotal (four patients) and total (two patients) villous atrophy were also detected in our patients. Treatment of SNCD is controversial. Leffler and co-workers ^[@R8]^ had argued against the use of GFD in patients with SNCD. However, Tursi and others ^[@R9]^ reported histopathological improvement in 23 patients and concluded that prescription of gluten restriction is warranted in such patients. In our study, nine patients showed clinical response to GFD over the duration of 6 to 12 months; however, histological response could be assessed in seven patients only as repeat endoscopy and biopsy was not performed in five patients. Among the seven patients, three showed histological improvement in villous architecture, three showed no change in histology, while one showed worsening of villous atrophy, as shown in [table 1](#T1){ref-type="table"}.

SNCD is an uncommon disease and to the best of our knowledge, the largest number of patients reported was 20 over a period of 10 years.^[@R5]^ This is the first report from Pakistan, incorporating 12 patients over a period of 6 years, in which the clinicopathological characteristics of SNCD and its response to GFD have been addressed. We have also reported SNCD in patients with subtotal and total villous atrophy, which has not been described before.

This study has some limitations, too. The sample size is small. It has originated from a single center. Repeat duodenal biopsy was not performed in all patients to document histological improvement. Responses to GFD and gluten challenge tests with histological confirmation were not used as diagnostic criteria. And the follow-up is short. Despite the above limitations, we believe that this study will help in understanding the full spectrum of SNCD.

DVA with negative celiac serology requires exclusion of a list of diseases, which requires a battery of tests. Like DeGaetani and colleagues ^[@R5]^, we also propose that HLA DQ2 and/or HLA DQ8 should be performed as the first test in such patients to reduce mental stress of undergoing many negative results and to decrease the economical burden of the country.

In conclusion, the diagnosis of SNCD is rewarding as it responds favorably to GFD in most patients. HLA serology provides an important tool for the diagnosis of this entity.

The authors declare no conflict of interest related to this work.
